Characteristic Cochlear Hypoplasia in Patients with Walker-Warburg Syndrome: A Radiologic Study of the Inner Ear in \(\alpha\)-Dystroglycan–Related Muscular Disorders


ABSTRACT

BACKGROUND AND PURPOSE: Walker-Warburg syndrome, muscle-eye-brain disease, and Fukuyama congenital muscular dystrophy are \(\alpha\)-dystroglycan–related muscular disorders associated with brain malformations and eye abnormalities in which no structural inner ear abnormality has been described radiologically. We collected patients from 6 tertiary pediatric hospitals and reported the radiologic features and frequency of inner ear dysplasias.

MATERIALS AND METHODS: Patients previously diagnosed clinicoradiologically with Walker-Warburg syndrome, muscle-eye-brain disease, or Fukuyama congenital muscular dystrophy were included. We recorded the pathogenic variant, when available. Brain MR imaging and/or CT findings were reviewed in consensus, and inner ear anomalies were classified according to previous description in the literature. We then correlated the clinicoradiologic phenotype with the inner ear phenotype.

RESULTS: Thirteen patients fulfilled the criteria for the Walker-Warburg syndrome phenotype, 8 for muscle-eye-brain disease, and 3 for Fukuyama congenital muscular dystrophy. A dysplastic cochlea was demonstrated in 17/24. The most frequent finding was a pronounced cochlear hypoplasia type 4 with a very small anteriorly offset turn beyond the normal-appearing basal turn (12/13 patients with Walker-Warburg syndrome and 1/11 with muscle-eye-brain disease or Fukuyama congenital muscular dystrophy). Two of 8 patients with muscle-eye-brain disease, 1/3 with Fukuyama congenital muscular dystrophy, and 1/13 with Walker-Warburg syndrome showed a less severe cochlear hypoplasia type 4. The remaining patients without Walker-Warburg syndrome were healthy. The vestibule and lateral semicircular canals of all patients were normal. Cranial nerve VIII was present in all patients with diagnostic MR imaging.

CONCLUSIONS: Most patients with the severe \(\alpha\)-dystroglycanopathy Walker-Warburg syndrome phenotype have a highly characteristic cochlear hypoplasia type 4. Patients with the milder variants, muscle-eye-brain disease and Fukuyama congenital muscular dystrophy, more frequently have a normal cochlea or milder forms of hypoplasia.

ABBREVIATIONS: CH = cochlear hypoplasia; CH4 AOUT = cochlear hypoplasia type 4 with anterior offset of the upper turn; FCMD = Fukuyama congenital muscular dystrophy; MEB = muscle-eye-brain disease; SNHL = sensorineural hearing loss; WWS = Walker-Warburg syndrome

The \(\alpha\)-dystroglycanopathies constitute a heterogeneous group of autosomal recessive disorders associated with muscular dystrophy due to a functional defect in the glycosylation of \(\alpha\)-dystroglycan, a cellular membrane adhesion complex that forms a bridge between the cytoskeleton and components of the extracellular matrix such as laminin. Most dystroglycanopathies involve a number of genes that code for glycosyltransferases, affecting the complex glycosylation of \(\alpha\)-dystroglycan and therefore limiting its ability to bind the extracellular-matrix ligands.
(secondary dystroglycanopathies). Rare mutations in dystroglycan itself are also recognized (primary dystroglycanopathies).

Mutations in at least 18 genes have been found to be involved in the glycosylation of α-dystroglycan, and the list is growing. However, a precise genotype-phenotype correlation is not possible, and the disease spectrum includes multiple phenotypes with overlapping clinical features and severity. This is because the effect of the mutation on the protein is more important than the gene per se because of the different degrees of α-dystroglycan hypoglycosylation.

Among these phenotypes, at the most severe end of the spectrum, Walker-Warburg syndrome (WWS), muscle-eye-brain disease (MEB), and Fukuyama congenital muscular dystrophy (FCMD) demonstrate brain malformations and ocular abnormalities, in addition to muscular dystrophy. Not surprisingly, the presence of malformations of cortical development of variable severity is associated with epilepsy and language deficits. The characteristic malformations of cortical development in these patients, a cobblestone lissencephaly/polymicrogyria-like cortex, result from variable-sized gaps in the pial basement membrane and overmigration of neuronal cells, related to the role of α-dystroglycan in the developing brain functioning as a link between radial glial cells and the pial basement membrane.

Genetic mutations are an increasingly recognized cause of congenital hereditary sensorineural hearing loss (SNHL) and can be associated with various types of inner ear dysplasias. Syndromic associations have also been described, with multiple additional abnormalities involving other organ systems and, in some cases, recognition of a specific type of inner ear dysplasia that can guide genetic testing.

There are only a few anecdotal reports of hearing loss in muscular dystrophy, including α-dystroglycanopathies, but no structural abnormality has been described in a series of patients, to our knowledge.

We hereby report the radiologic characteristics, frequency, and correlation with the clinicoradiologic phenotype of inner ear dysplasia encountered in a population of patients with α-dystroglycanopathy collected from 6 tertiary pediatric hospitals.

MATERIALS AND METHODS

Cases were identified using the electronic patient record system of each institution, searching for WWS, MEB, and FCMD diagnoses and adding relevant keyword searches (eg, “α-dystroglycanopathy,” “congenital muscular dystrophy,” “cobblestone cortex,” and “cerebellar cysts”). Appropriate governance permissions from each site were obtained.

Only patients previously diagnosed clinicoradiologically as having WWS, MEB, or FCMD were included. According to previous literature, a WWS phenotype was defined with observation of very early neurologic symptom onset (prenatally or at birth) and extreme brain abnormalities: complete agyria or severe lissencephaly/cobblestone, marked hydrocephalus, severe cerebellar hypoplasia/dysplasia, and complete or partial absence of the corpus callosum. In addition, a severely hypoplastic and kinked brain stem was determined as a characteristic feature of WWS and considered an inclusion criterion in this category. Eye abnormalities include congenital cataracts, microphthalmia, and buphthalmos.

MEB and FCMD phenotypes were defined when brain abnormalities were less severe than those seen with WWS: pachygyria/polymicrogyria-like/cobblestone cortex with preferential frontoparietal involvement, cerebellar hypoplasia, and less severe brain stem anomalies, including a posterior “bowing” (a posterior concavity less severe than that observed in kinked brain stem). Despite a recognized radiologic overlap between MEB and FCMD, clinically, cardiac and respiratory problems with less severe epilepsy were more typical of FCMD, while more severe ocular abnormalities and the absence of cardiac or respiratory features were more in keeping with MEB.

When pathogenic genetic mutations were available, they were recorded; however, given the weak genotype/phenotype correlation in these disorders, we correlated the clinicoradiologic phenotype with the inner ear phenotype.

The authors retrospectively reviewed, by consensus, the brain MR imaging and/or CT findings (anonymized). MRIs were acquired on different scanners (both 1.5T and 3T) and with different protocols. An axial T2 brain sequence (section thickness, 2–3 mm) or a high-resolution 3D steady-state sequence of the internal auditory meatus was used to assess the inner ears. The axial T2 was considered diagnostic when cochleae were visualized in at least 2 slices (basal turns in the most caudal one and middle/apical turns in the cranial one).

Available CT scans were acquired with a standard brain protocol and subsequent bone algorithm reconstructions (1-mm section thickness).

Inner ear anomalies were reviewed and classified according to previous literature. More specifically, cochlear hypoplasia (CH) was defined as a cochlea with a small external size and a less than normal number of 2½–2½ turns. The definition of each CH subtype was previously described in histologic and radiologic studies: 1) CH-1: tiny budlike cochlea without an internal structure; 2) CH-2: a small cochlea with a modiolus or interscalar septa, which are present but defective; 3) CH-3: the internal and external architecture (modiolus, interscalar septa) is similar to that of a normal cochlea, but the overall size is smaller with fewer or shorter turns; and 4) CH-4: a small cochlea with a normal basal turn but hypoplastic middle and apical turns.

In addition, an anterior offset of the cochlear middle turn was recorded when there was “anteromedial angulation and displacement of the middle and apical turns of the cochlea away from the basal turn,” similar to the cochlea malformation described in branchio-oto-renal syndrome.

Patients who did not fulfill the clinicoradiologic criteria for WWS, MEB, or FCMD or with images suboptimal for cochlear assessment were excluded.

RESULTS

After initial research, we excluded 3 patients: 2 with MEB with suboptimal images and an aborted 20-week fetus with severe cortical malformation and kinking of the brain stem but without clinical criteria or genetic mutations available at the time of the report and no postnatal MR imaging performed.

Twenty-four patients with congenital muscular dystrophy due to secondary dystroglycanopathies were found. Fourteen (14/24) were males (age range, 1 day to 21 years). Thirteen of 24 showed a
Dysplastic cochlear morphology was found in 17/24; in all cases, the abnormality was bilateral and symmetric. Cochlear morphology appeared normal in 7/24 (Table).

The most frequent finding was characteristic cochlear hypoplasia with a normal basal turn and extremely hypoplastic upper turns that appeared offset anteriorly with respect to the basal turn. Given the normal basal turn, this was classified as a CH type 4 (Figs 1 and 2).

This morphology was found in 13/24 patients. Most interestingly, the pronounced CH4 with an anterior offset of the upper turn (CH4 AOUT) was present in 12/13 of patients with WWS but only 1/11 of the remaining phenotypes, a patient with MEB. The remaining patient with WWS also had a small cochlea with a normal basal turn (CH4AOUT) but with better developed upper turns, similar to the other less severe CH4 found in some of the patients with MEB and FCMD (Fig 3). Among the MEB phenotypes, 5/8 patients had normal cochleae, 1/8 had CH4 AOUT, and 2/8 showed a less severe form of CH4. Patients with

**FIG 1.** Axial CT with thin bone reformats in patient 1. The WWS phenotype and POMT1 variant (A, B, and C) show a characteristic CH4 AOUT with a normal basal turn (arrows in A and B) and a very hypoplastic and anteromedially displaced upper part of the cochlea (dashed arrow in C). The abnormality was symmetric on both sides. Note the normal appearance of the semicircular canals and vestibule. The vestibular aqueducts (asterisk in A and B), despite looking slightly enlarged on subjective analysis, were within normal limits when measured. A normal cochlea for comparison (D, E, and F) shows well-developed middle and apical turns (arrowhead in F).

WWS phenotype; 8/24, an MEB phenotype; and 3/24, an FCMD phenotype. Genetic confirmation was available in 17/24 cases: 5 POMGNT1, 4 POMT1, 2 POMT2, 3 FKRP, 1 FKTN, 1 B3GNT1, and 1 POMGNT2.
FCMD had normal cochleae in 2/3 cases, while 1 subject had a less severe form of CH4. In all patients, we found that the vestibules and semicircular canals were normal (Fig 2). The vestibulocochlear nerves were bilaterally present in all cases (on axial T2 images).

No audiometric correlation was available because hearing function is not routinely evaluated in these patients.

**DISCUSSION**

Mutations in 18 currently known genes can cause defective glycosylation of α-dystroglycan and, consequently, a subset of congenital muscular dystrophies called secondary dystroglycanopathies. These diseases vary in severity from mild adult-onset limb-girdle muscular dystrophy to more severe phenotypes with early-onset and eye and brain involvement.3 Brain malformations have been extensively described in patients at the severe end of the clinical spectrum and were used as one of the diagnostic criteria, even before the genetic profile was recognized.14

![FIG 2. 3D volume-rendering of the CH4 AOUT in patient 2 with a WWS phenotype and POMT1 variant (A) in comparison with a healthy control (B). Note the marked cochlear hypoplasia in A (arrow) in comparison with normal 2½ cochlear turns in B. The vestibule and lateral semicircular canals are normal in both patients.](image)

An important concept, useful in the interpretation of our data, is that in secondary dystroglycanopathies, a precise genotype/phenotype correlation is not possible because the mutations in the same gene can cause a variety of different phenotypes and these diseases should be considered as a clinicoradiologic spectrum. This is mainly due to the effect of individual mutations on the glycosylation of α-dystroglycan, with WWS representing the extremely severe variant.3,4 A relatively milder form of congenital muscular dystrophy with structural brain involvement is represented by MEB/FCMD, usually associated with founder mutations in POMGNT1 and FKTN, but less frequently associated with most of the other genes.4,11

Thus, we decided to correlate the clinicoradiologic phenotype (rather than genotype) with inner ear appearances, and in doing so, we found that 100% of patients with WWS showed striking cochlear abnormalities (12/13 had a characteristic CH4 AOUT), while only 4/11 with MEB/FCMD had cochlear abnormalities and only 1 had CH4 AOUT. Therefore, the cochlea seems to predict the brain to some extent.

Very few reports of children with congenital muscular dystrophies and SNHL have been previously published.15 Carss et al1 published a case series of 8 patients with α-dystroglycanopathy due to GMPPB variants: among them, a patient with an MED/FCMD phenotype and “pontine and cerebellar hypoplasia” had SNHL. Later on, a patient with a FKRP variant was reported to have unusually severe eye abnormalities and SNHL.16 Bilateral SNHL has been recently reported in 12 subjects with the B3GALNT2 variant, severe brain malformations (mostly cobblestone/polymicrogyria spectrum and pontocerebellar hypoplasia/dysplasia), and epilepsy, but no morphologic description of the inner ear anomalies was available.17 Furthermore, microstructural changes in the cochlea have been described in a laminin-deficient dy mouse model of congenital muscular dystrophy, implying that laminin is critical in the cochlear function and development.18 The role of the laminin is further supported by the presence of antibodies against laminin in various forms of hearing loss.19 Finally, SNHL has been noted in a patient with limb-girdle muscular dystrophy20 and in 2 siblings with arthrogryposis multiplex congenita and cobblestone lissencephaly.21

Hence, hearing loss may be a largely under-recognized feature of the severe α-dystroglycanopathies with central nervous system involvement, noting that the genetic link is not as yet well-established.

It is interesting that all the inner ear dysplasias in this series exclusively involved the cochlear portion of the labyrinth. No other abnormality was found in the inner ear (normal vestibule and semicircular canals).
A number of gene families are of critical importance in the embryogenesis of the otic capsule–derived structures (eg, FOX, Dlx, FGF, PAX, and SOX), and correlations have been found between some pathogenic genes and characteristic inner ear malformations. Moreover, some of these genes are significantly involved in the embryogenesis of other systems, producing quite notable syndromic associations.

According to the “compartment boundary model” of inner ear development, particular genes are involved in the development of the ventral portion of the otic capsule (ie, cochlear morphogenesis), while others are involved in the development of the vestibule or semicircular canals.

Although much is still unknown about the “symphony of inner ear development control genes” (as described by Chattarjee et al), we know that for instance, Shh maintains Pax2 in the medial and ventral wall of the forming otic vesicle determining the cochlear fate, while Wnt and Dlx5/Dlx6 are involved in the development of the vestibule and semicircular canals.

In fact, Pax2 knockout mice demonstrate an absent cochlea, while other genes can account for the loss of ≥1 semicircular canal. It is then possible that in dystroglycanopathies, the functions of ≥1 gene determining exclusively the cochlear fate, rather than the development of the otic capsule as a whole, are impaired.

There is other evidence that may be relevant in explaining the specific cochlear phenotype in our patients: 1) The sensory precursor cells are under the control of many cyclin-dependent kinase inhibitors, including p27, which is more active when the cochlea starts to develop the middle and apical turns and after the development of the basal turn (exactly when the cochlear development is arrested in case of CH4); and 2) the G2 domain (a widely distributed protein motif) is present in POMGnTI (mutated in MEB) but also in cases of nonsyndromic hearing loss.

Finally, insights can come from the embryology; according to Sennaroglu, CH-4 is likely a genetically determined hypoplasia in which the arrest in the membranous labyrinth development happens between the 10th and 20th week before the middle and apical turns reach normal size but the basal turn has already fully developed. Therefore, it is possible that the CH4 morphology in patients with WWS is due to a genetically determined arrested development between the 10th and 20th week, associated with the malfunction of genes that are specifically involved in the development of the cochlea. Cochlear hypoplasia type 4 can also be found in other genetically determined syndromes and does not constitute a pathognomonic feature of dystroglycanopathies. However, in the appropriate clinicoangiologic context, such a marked hypoplastic phenotype seems to be fairly specific for the WWS phenotype.

The main limitation of this study is its retrospective nature and the fact that all except 2 MR imaging studies consisted of routine brain sequences rather than detailed sequences for the inner ear. Nevertheless, on CT and 2- to 3-mm axial T2-weighted images of the brain, the cochlea can be adequately assessed by experienced pediatric neuroradiologists in consensus. If possible, adding a high-resolution 3D steady-state sequence to the MR imaging protocol would be ideal to depict the abnormality. Also, when available, we found that thin bone reformats of a CT of the head obtained for hydrocephalus are enough to characterize the cochlear abnormalities in those patients.

Another potential bias lies in the clinical diagnosis of these syndromes, which, in itself, is often challenging and commonly presents with overlapping features. To avoid misinterpretation of the correct diagnosis, a clinical and radiologic analysis was required to confirm that each subject fulfilled the criteria for each syndrome.

CONCLUSIONS

This is the first radiologic description of inner ear dysplasias in a relatively large series of patients with α-dystroglycanopathies characterized by distinct pronounced hypoplasia of the middle cochlear turns, which appears anteriorly offset from the basal turn, with an absent/deficient apical turn in most WWS phenotypes and with less frequent and less marked dysplasia (but again limited to the cochlea) in the MEB and FCMD phenotypes. This evidence lays the foundation for further studies investigating the genetic link between ear development and α-dystroglycanopathies, which may help in understanding the factors specifically responsible for cochlear development.

ACKNOWLEDGMENTS

We would like to thank Mr Juling Ong, consultant craniofacial and pediatric plastic surgeon at Great Ormond Street Hospital, for supervising the 3D reformating and 3D printing of the cochlear abnormalities.

References


7. Sennaroğlu L. Histopathology of inner ear malformations: do we have enough evidence to explain pathophysiology?. Cochlear Implants Int 2016;17:3–20 CrossRef Medline